Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "Families"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"Canadian Agency for Drugs and Technologies in Health"
language:"English"
Showing
1
-
9
of
9
Search:
'"Families"'
,
query time: 0.02s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Patient- and family-centered care initiatives in acute care settings : a review of the clinical evidence, safety, and guidelines
Published 2015
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Professional-
Family
Relations...
”
Read Now
2
Clinical review report: Burosumab (Crysvita) (Kyowa Kirin limited) : indication: for the treatment of x-linked hypophosphatemia in adult and pediatric patients one year of age and...
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Familial
Hypophosphatemic Rickets / drug therapy...
”
Read Now
3
CADTH Canadian drug expert committee recommendation: Inotersen (Tegsedi -- Akcea Therapeutics, Inc.) : indication : treatment of polyneuropathy in adults with hereditary transthyre...
Published 2019
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Amyloid Neuropathies,
Familial
/ drug therapy...
”
Read Now
4
Clinical review report: Inotersen (Tegsedi) (Akcea therapeutics, inc.) : indication: stage I or II polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATT...
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Amyloid Neuropathies,
Familial
/ drug therapy...
”
Read Now
5
Pharmacoeconomic review report: Inotersen (Tegsedi) (Akcea Therapeutics, Inc.) : indication : stage I or II polyneuropathy in adults with hereditary transthyretin-mediated amyloido...
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Amyloid Neuropathies,
Familial
/ drug therapy...
”
Read Now
6
Clinical review report: Patisiran (Onpattro) : (Alnylam Netherlands B.V.)
Published 2019
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Amyloid Neuropathies,
Familial
/ drug therapy...
”
Read Now
7
CADTH Canadian drug expert committee recommendation: Burosumab (Crysvita -- Kyowa Kirin Limited) : indication : treatment of x-linked hypophosphatemia
Published 2020
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...
Familial
Hypophosphatemic Rickets / drug therapy...
”
Read Now
8
CADTH Canadian drug expert committee recommendation: Patisiran (Onpattro -- Alnylam Netherlands BV) : indication : for the treatment of polyneuropathy in adult patients with heredi...
Published 2019
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Amyloid Neuropathies,
Familial
/ drug therapy...
”
Read Now
9
Pharmacoeconomic review report: Patisiran (Onpattro) : (Alnylam Netherlands B.V.)
Published 2019
Canadian Agency for Drugs and Technologies in Health
Subjects:
“
...Amyloid Neuropathies,
Familial
/ drug therapy...
”
Back
Narrow Search
Remove Filters
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Clear Filter
Language: English
Year of Publication
From:
To:
Classification
610 - Medicine & health
6
140 - Specific philosophical schools
2
330 - Economics
2
Language
English
Collection
National Center for Biotechnology Information
9
Author
Canadian Agency for Drugs and Technologies in Health
CADTH Canadian Drug Expert Committee
1
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&filter%5B%5D=language%3A%22English%22&lookfor=%22Families%22&type=Subject
Send by Email
×
Loading...